[go: up one dir, main page]

UY37506A - Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip - Google Patents

Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip

Info

Publication number
UY37506A
UY37506A UY0001037506A UY37506A UY37506A UY 37506 A UY37506 A UY 37506A UY 0001037506 A UY0001037506 A UY 0001037506A UY 37506 A UY37506 A UY 37506A UY 37506 A UY37506 A UY 37506A
Authority
UY
Uruguay
Prior art keywords
trigonal
glucagón
glp1
new compounds
gip receptors
Prior art date
Application number
UY0001037506A
Other languages
English (en)
Inventor
Dieter Kadereit
Michael Wagner
Martin Bossart
Andreas Evers
Torsten Haack
Katrin Lorenz
Stefania Pfeiffer-Marek
Martin Lorenz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY37506A publication Critical patent/UY37506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agonistas trigonales de los receptores de GLP-1 /glucagón / GIP y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, incluyendo diabetes y obesidad, así como para la reducción del exceso de ingesta de alimentos
UY0001037506A 2016-12-02 2017-12-01 Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip UY37506A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306604 2016-12-02

Publications (1)

Publication Number Publication Date
UY37506A true UY37506A (es) 2018-06-29

Family

ID=57542935

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037506A UY37506A (es) 2016-12-02 2017-12-01 Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip

Country Status (23)

Country Link
US (1) US10538567B2 (es)
EP (1) EP3548508B1 (es)
JP (1) JP7100033B2 (es)
KR (1) KR102576872B1 (es)
CN (1) CN110023329B (es)
AR (1) AR110300A1 (es)
AU (1) AU2017367173B2 (es)
BR (1) BR112019011228A2 (es)
CA (1) CA3045377A1 (es)
CL (1) CL2019001465A1 (es)
CO (1) CO2019006917A2 (es)
CR (1) CR20190313A (es)
DO (1) DOP2019000068A (es)
EA (1) EA201991345A1 (es)
EC (1) ECSP19046893A (es)
IL (1) IL266984A (es)
MA (1) MA46955A (es)
MX (1) MX2019006429A (es)
PE (1) PE20191143A1 (es)
PH (1) PH12019501216A1 (es)
TW (1) TW201833132A (es)
UY (1) UY37506A (es)
WO (1) WO2018100134A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
US11028123B2 (en) 2018-04-10 2021-06-08 Sanofi-Aventis Deutschland Gmbh Capping of unprotected amino groups during peptide synthesis
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
CN114786706A (zh) * 2019-10-04 2022-07-22 韩美药品株式会社 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途
PH12022551101A1 (en) 2019-11-11 2023-11-13 Boehringer Ingelheim Int Npy2 receptor agonists
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
CA3188884A1 (en) * 2020-08-14 2022-02-17 Seungjae Baek Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用
US20240299552A1 (en) * 2020-12-16 2024-09-12 Zealand Pharma A/S Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
BR112023025387A2 (pt) * 2021-06-25 2024-02-27 Lilly Co Eli Usos de tirzepatida
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
TW202404997A (zh) * 2022-05-27 2024-02-01 韓商Ｄ＆Ｄ製藥科技股份有限公司 肽組合物及其使用方法
AU2023348864A1 (en) * 2022-09-28 2025-03-20 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg/gip triple-receptor agonist and use thereof
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN119241684B (zh) * 2024-11-22 2025-02-25 徐州医科大学 一种肠促胰岛素类似物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050083713A (ko) 2002-10-02 2005-08-26 질랜드 파마 에이/에스 안정화된 엑센딘-4 화합물
US20080019911A1 (en) * 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
HUE028072T2 (en) 2008-06-17 2016-11-28 Univ Indiana Res & Tech Corp GIP-based agonists for the treatment of metabolic disease and obesity
IN2012DN00377A (es) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR20130132931A (ko) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤 유사체들
TWI599575B (zh) * 2012-06-21 2017-09-21 印第安納大學科技研究公司 表現ｇｉｐ受體活性之胰高血糖素類似物
AU2013277372B2 (en) 2012-06-21 2018-03-29 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting GIP receptor activity
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA031428B1 (ru) 2012-12-21 2018-12-28 Санофи Функционализированные производные эксендина-4
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609798A (zh) 2013-12-13 2016-03-16 賽諾菲公司 Ｅｘｅｎｄｉｎ－４胜肽類似物
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip

Also Published As

Publication number Publication date
CO2019006917A2 (es) 2019-07-10
EA201991345A1 (ru) 2019-11-29
JP7100033B2 (ja) 2022-07-12
KR20190085141A (ko) 2019-07-17
CN110023329B (zh) 2024-05-03
CA3045377A1 (en) 2018-06-07
WO2018100134A1 (en) 2018-06-07
KR102576872B1 (ko) 2023-09-12
ECSP19046893A (es) 2019-07-31
PE20191143A1 (es) 2019-09-02
TW201833132A (zh) 2018-09-16
IL266984A (en) 2019-07-31
AU2017367173A1 (en) 2019-07-18
BR112019011228A2 (pt) 2019-10-15
PH12019501216A1 (en) 2019-08-19
EP3548508B1 (en) 2021-10-27
EP3548508A1 (en) 2019-10-09
CN110023329A (zh) 2019-07-16
MX2019006429A (es) 2019-08-21
DOP2019000068A (es) 2019-05-31
MA46955A (fr) 2021-05-19
AR110300A1 (es) 2019-03-13
US10538567B2 (en) 2020-01-21
AU2017367173B2 (en) 2022-03-24
JP2019536796A (ja) 2019-12-19
CL2019001465A1 (es) 2019-10-18
CR20190313A (es) 2019-09-11
US20180155406A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CO2019006917A2 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
UY35231A (es) Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
BR112016022754A2 (pt) derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon
UY35072A (es) Derivados de exendina-4 como agonistas duales de GLP1/glucagón
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112016023039A2 (pt) agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4
AR102712A1 (es) Agonistas parciales del receptor de insulina
UY34859A (es) Análogos peptídicos de la exendina 4.
CO7400885A2 (es) Análogos de glucagón
UA118558C2 (uk) Пептидна сполука
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
CR20170470A (es) Tratamiento de pacientes con diabetes mellitus tipo 2
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)